Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
Trial details
- Registry ID
- NCT02143973
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as nalbuphine
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic PruritusNCT02143973 | Trevi Therapeutics | Phase 2, Phase 3 | Completed | 2016-01Actual |
| Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo NodularisNCT02174432 | Trevi Therapeutics | Phase 2, Phase 3 | Completed | 2017-09-03Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |